☰

Yan Liu - Publications

Affiliations: 
2015 Harvard University, Cambridge, MA, United States 
Tree Info Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Wong KK, Liu Y, Li Y, Wang X, Liu F, Gao P, Quinn MM, Li F, Merlino AA, Benes CH, Liu Q, Gray NS. Gemcitabine and Chk1 inhibitor AZD7762 synergistically suppress the growth of Lkb1-deficient lung adenocarcinoma. Cancer Research. PMID 28754670 DOI: 10.1158/0008-5472.Can-17-0567  0.323
2017 Adeegbe D, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, Dries R, Li Y, Liu S, Wang X, Warner-Hatten T, Castrillon J, Yuan GC, Poudel-Neupane N, Zhang H, et al. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-small Cell Lung Cancer. Cancer Discovery. PMID 28408401 DOI: 10.1158/2159-8290.Cd-16-1020  0.324
2016 Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, Lin CY, Perry JA, Lawlor MA, Federation A, De Raedt T, Li YY, Liu Y, Duarte MA, Zhang Y, et al. Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer. Cancer Discovery. PMID 27312177 DOI: 10.1158/2159-8290.Cd-16-0164  0.306
2015 Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M, Bonnette WG, Gorman SA, Degenhardt Y, Bai Y, McCabe MT, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 28: 57-69. PMID 26175415 DOI: 10.1016/J.Ccell.2015.06.002  0.31
2015 Smitheman K, Cusan M, Liu Y, Butticello M, Pappalardi M, Foley J, Federowicz K, Aller GV, Kasparec J, Tian X, Suarez D, Schneck J, Carson J, McDevitt P, Ho T, et al. Abstract 3513: Inhibition of LSD1 for the treatment of cancer Cancer Research. 75: 3513-3513. DOI: 10.1158/1538-7445.Am2015-3513  0.352
2014 Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, ... Liu Y, et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 26: 909-22. PMID 25490451 DOI: 10.1016/J.Ccell.2014.10.019  0.308
2013 Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discovery. 3: 870-9. PMID 23715154 DOI: 10.1158/2159-8290.Cd-13-0015  0.309
2013 Kruger RG, Mohammad H, Smitheman K, Cusan M, Liu Y, Pappalardi M, Federowicz K, Van Aller G, Kasparec J, Tian X, Suarez D, Rouse M, Schneck J, Carson J, McDevitt P, et al. Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia Blood. 122: 3964-3964. DOI: 10.1182/Blood.V122.21.3964.3964  0.339
2012 Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 483: 613-7. PMID 22425996 DOI: 10.1038/Nature10937  0.312
2012 Liu Y, Cowley GS, Cohoon TJ, Root DE, Kwok-kin W. Abstract LB-260: Identification of DTYMK and CHEK1 as therapeutic targets in LKB1 mutant non-small cell lung cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-260  0.324
2011 Asai T, Liu Y, Bae N, Nimer SD. The p53 tumor suppressor protein regulates hematopoietic stem cell fate. Journal of Cellular Physiology. 226: 2215-21. PMID 21660944 DOI: 10.1002/Jcp.22561  0.317
2009 Liu Y, Elf SE, Asai T, Miyata Y, Liu Y, Sashida G, Huang G, Di Giandomenico S, Koff A, Nimer SD. The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior. Cell Cycle (Georgetown, Tex.). 8: 3120-4. PMID 19755852 DOI: 10.4161/Cc.8.19.9627  0.318
2009 Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, Deblasio A, Menendez S, Antipin J, Reva B, Koff A, Nimer SD. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 4: 37-48. PMID 19128791 DOI: 10.1016/J.Stem.2008.11.006  0.319
2009 Asai T, Liu Y, Giandomenico SD, Deblasio A, Menendez S, Antipin J, Reva B, Wevrick R, Nimer SD. Necdin Regulates Hematopoietic Stem Cell Quiescence and Sensitivity to Genotoxic Stress. Blood. 114: 379-379. DOI: 10.1182/Blood.V114.22.379.379  0.304
2007 Yao JJ, Liu Y, Lacorazza HD, Soslow RA, Scandura JM, Nimer SD, Hedvat CV. Tumor promoting properties of the ETS protein MEF in ovarian cancer. Oncogene. 26: 4032-7. PMID 17213815 DOI: 10.1038/Sj.Onc.1210170  0.333
2006 Liu Y, Hedvat CV, Mao S, Zhu XH, Yao J, Nguyen H, Koff A, Nimer SD. The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. Molecular and Cellular Biology. 26: 3114-23. PMID 16581786 DOI: 10.1128/Mcb.26.8.3114-3123.2006  0.306
2006 Lacorazza HD, Yamada T, Liu Y, Miyata Y, Sivina M, Nunes J, Nimer SD. The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells. Cancer Cell. 9: 175-87. PMID 16530702 DOI: 10.1016/J.Ccr.2006.02.017  0.301
Show low-probability matches.